DK1244650T3 - Arylaminderivater og deres anvendelse som antitelomerasemidler - Google Patents

Arylaminderivater og deres anvendelse som antitelomerasemidler

Info

Publication number
DK1244650T3
DK1244650T3 DK00985339T DK00985339T DK1244650T3 DK 1244650 T3 DK1244650 T3 DK 1244650T3 DK 00985339 T DK00985339 T DK 00985339T DK 00985339 T DK00985339 T DK 00985339T DK 1244650 T3 DK1244650 T3 DK 1244650T3
Authority
DK
Denmark
Prior art keywords
agents
antithelomerase
arylamine derivatives
concerns
arylamine
Prior art date
Application number
DK00985339T
Other languages
English (en)
Inventor
Jean-Francois Riou
Abdelazize Laoui
Patrick Mailliet
Jean-Louis Mergny
Francois Lavelle
Odile Petitgenet
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9915031A external-priority patent/FR2801588B1/fr
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Application granted granted Critical
Publication of DK1244650T3 publication Critical patent/DK1244650T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/46—Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/54—Three nitrogen atoms
    • C07D251/70—Other substituted melamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
DK00985339T 1999-11-29 2000-11-27 Arylaminderivater og deres anvendelse som antitelomerasemidler DK1244650T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9915031A FR2801588B1 (fr) 1999-11-29 1999-11-29 Derives chimiques et leur application comme agent antitelomerase
FR0010561 2000-08-11
PCT/FR2000/003310 WO2001040218A1 (fr) 1999-11-29 2000-11-27 Derives arylamines et leur application comme agent antitelomerase

Publications (1)

Publication Number Publication Date
DK1244650T3 true DK1244650T3 (da) 2003-10-20

Family

ID=26212577

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00985339T DK1244650T3 (da) 1999-11-29 2000-11-27 Arylaminderivater og deres anvendelse som antitelomerasemidler

Country Status (27)

Country Link
EP (1) EP1244650B1 (da)
JP (1) JP2003515604A (da)
KR (1) KR20020058043A (da)
CN (1) CN1402722A (da)
AT (1) ATE243692T1 (da)
AU (1) AU2179001A (da)
BG (1) BG106753A (da)
BR (1) BR0015992A (da)
CA (1) CA2392507A1 (da)
CO (1) CO5251431A1 (da)
CZ (1) CZ20021849A3 (da)
DE (1) DE60003583T2 (da)
DK (1) DK1244650T3 (da)
EA (1) EA200200616A1 (da)
EE (1) EE200200263A (da)
ES (1) ES2202206T3 (da)
HU (1) HUP0204429A2 (da)
IL (1) IL149402A0 (da)
MX (1) MXPA02005276A (da)
NO (1) NO20022528L (da)
PE (1) PE20010912A1 (da)
PL (1) PL355667A1 (da)
PT (1) PT1244650E (da)
SK (1) SK7402002A3 (da)
UY (1) UY26456A1 (da)
WO (1) WO2001040218A1 (da)
YU (1) YU38102A (da)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003511378A (ja) 1999-10-07 2003-03-25 アムジエン・インコーポレーテツド トリアジン系キナーゼ阻害薬
WO2001055116A2 (en) * 2000-01-28 2001-08-02 Astrazeneca Ab Quinoline derivatives and their use as aurora 2 kinase inhibitors
WO2001060816A1 (en) 2000-02-17 2001-08-23 Amgen Inc. Kinase inhibitors
AU2001282268A1 (en) * 2000-08-08 2002-02-18 Aventis Pharma S.A. Phenantridine derivatives and their use as anti-telomerase agent
ATE430742T1 (de) * 2000-12-21 2009-05-15 Smithkline Beecham Corp Pyrimidinamine als angiogenesemodulatoren
FR2821355A1 (fr) * 2001-02-23 2002-08-30 Aventis Pharma Sa Derives chimiques et leur application comme agent antitelomerase
FR2822468B1 (fr) * 2001-03-23 2008-06-20 Aventis Pharma Sa Derives chimiques et leur application comme agent anti-telomerase
CO5380035A1 (es) * 2001-03-23 2004-03-31 Aventis Pharma Sa Derivados quimicos y su aplicacion como agente antitelomerasa
US6887873B2 (en) 2001-03-23 2005-05-03 Aventis Pharma S.A. Triazine derivatives and their application as antitelomerase agents
WO2002096903A2 (fr) * 2001-05-28 2002-12-05 Aventis Pharma S.A. Derives chimiques et leur application comme agent antitelomerase
US6939874B2 (en) * 2001-08-22 2005-09-06 Amgen Inc. Substituted pyrimidinyl derivatives and methods of use
US7115617B2 (en) 2001-08-22 2006-10-03 Amgen Inc. Amino-substituted pyrimidinyl derivatives and methods of use
US7132423B2 (en) 2001-09-21 2006-11-07 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
US7112587B2 (en) 2001-09-21 2006-09-26 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
US7173032B2 (en) 2001-09-21 2007-02-06 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
US7163943B2 (en) 2001-09-21 2007-01-16 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
US7169785B2 (en) 2001-09-21 2007-01-30 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
WO2003045313A2 (en) 2001-11-27 2003-06-05 Merck & Co. Inc. 2-aminoquinoline compounds
JP2006503028A (ja) * 2002-09-10 2006-01-26 ファルマシア・イタリア・エッセ・ピー・アー 抗腫瘍薬としての置換ピリジン誘導体
AU2003275726A1 (en) * 2002-10-24 2004-05-13 Chong Kun Dang Pharmaceutical Corp. 2 - substituted heterocyclic compounds and antitumor composition comprising the same
FR2850970B1 (fr) * 2003-02-07 2006-07-07 Aventis Pharma Sa Derives chimiques se liant de maniere tres specifique aux structures d'adn en g-quadruplexe et leur application comme agent anticancereux specifique
JP4691041B2 (ja) * 2003-11-20 2011-06-01 チルドレンズ ホスピタル メディカル センター Ｇｔｐアーゼ阻害剤および使用方法
US7335770B2 (en) 2004-03-24 2008-02-26 Reddy U5 Therapeutics, Inc. Triazine compounds and their analogs, compositions, and methods
WO2007049057A2 (en) * 2005-10-28 2007-05-03 Iti Scotland Limited Novel fluorescent dyes and uses thereof
US7713987B2 (en) 2005-12-06 2010-05-11 Rigel Pharmaceuticals, Inc. Pyrimidine-2,4-diamines and their uses
KR100761869B1 (ko) * 2006-07-07 2007-10-04 김현기 트리아진 유도체 화합물 및 이를 포함하는 암 치료용조성물
US8138338B2 (en) * 2006-07-31 2012-03-20 Glaxosmithkline Llc Aurora kinase inhibitors from an encoded small molecule library
JP5325517B2 (ja) * 2007-10-12 2013-10-23 住友化学株式会社 ジベンゾオキセピン化合物の精製方法
JP2009102249A (ja) * 2007-10-22 2009-05-14 Sumitomo Chemical Co Ltd ジベンゾオキセピン化合物の結晶の製造方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9206768D0 (en) * 1992-03-27 1992-05-13 Jarman Michael New compounds for use in the treatment of cancer
US5770613A (en) * 1995-09-29 1998-06-23 Geron Corporation Telomerase inhibitors
JPH1160573A (ja) * 1997-08-22 1999-03-02 Nippon Kayaku Co Ltd トリアジン誘導体及びテロメラーゼ阻害剤
US6156763A (en) * 1998-02-04 2000-12-05 Board Of Regents, The University Of Texas System Inhibition of human telomerase by a g-quadruplex-interaction compound
DE19812879A1 (de) * 1998-03-24 1999-09-30 Bayer Ag Substituierte 2,4-Diamino-1,3,5-triazine

Also Published As

Publication number Publication date
BR0015992A (pt) 2002-08-06
DE60003583D1 (de) 2003-07-31
EP1244650A1 (fr) 2002-10-02
DE60003583T2 (de) 2004-05-13
ATE243692T1 (de) 2003-07-15
MXPA02005276A (es) 2002-11-07
PL355667A1 (en) 2004-05-04
HUP0204429A2 (hu) 2003-04-28
IL149402A0 (en) 2002-11-10
AU2179001A (en) 2001-06-12
PE20010912A1 (es) 2001-09-01
CZ20021849A3 (cs) 2002-08-14
WO2001040218A1 (fr) 2001-06-07
PT1244650E (pt) 2003-11-28
BG106753A (bg) 2003-02-28
CO5251431A1 (es) 2003-02-28
SK7402002A3 (en) 2002-11-06
JP2003515604A (ja) 2003-05-07
CN1402722A (zh) 2003-03-12
NO20022528D0 (no) 2002-05-28
KR20020058043A (ko) 2002-07-12
ES2202206T3 (es) 2004-04-01
EP1244650B1 (fr) 2003-06-25
YU38102A (sh) 2004-12-31
UY26456A1 (es) 2001-06-29
NO20022528L (no) 2002-05-28
EA200200616A1 (ru) 2002-10-31
CA2392507A1 (fr) 2001-06-07
EE200200263A (et) 2003-06-16

Similar Documents

Publication Publication Date Title
DK1244650T3 (da) Arylaminderivater og deres anvendelse som antitelomerasemidler
DE60112974D1 (en) Carbolinderivate
BG108268A (en) Pyrazolopyrimidines as therapeutic agents
NO20042635L (no) 5-Sulfanyl-ñH-1,2,4-triazol-derivater og deres anvendelse som medisin
ECSP034774A (es) Pirazolopirimmidinas como agentes terapeuticos
NO20020684L (no) 3(5)-aminopyrazolderivater, fremgangsmåtet for deres fremstilling og deres anvendelse som antitumormidler
NO20060971L (no) Pyridazinderivater og deres anvendelse som terapeutiske midler
DK1204649T3 (da) Arylmethylcarbonylaminothiazolderivater og deres anvendelse som antitumormidler
ATE231872T1 (de) Thiazolopyrimidinderivate
DK1525177T3 (da) Substituerede 1,3-diphenylprop-2-en-1-on-derivater, fremstilling og anvendelse deraf
DE60216233D1 (en) Carbolinderivate
MXPA03002911A (es) Compuestos quimicos.
WO2002096903A3 (fr) Derives chimiques et leur application comme agent antitelomerase
IS7137A (is) Samsett meðferð til meðhöndlunar á krabbameini
SE0101932D0 (sv) Pharmaceutical combinations
MXPA02012076A (es) Compuestos quimicos.
DK1097173T3 (da) Anvendelse af peptider af IL-2 og derivater deraf som terapeutiske midler
MXPA02012659A (es) Derivados de pirazindiona condensados.
SE9904377D0 (sv) Pharmaceutical combinations
WO2002070469A3 (en) Selective pde3b inhibitors and use of the same in therapy
DE60112960D1 (de) Kondensierte pyridoindolderivate
MY130957A (en) Triazine derivatives and their application as antitelomerase agents
DE60315288D1 (de) Cyanoguanidin prodrugs
MXPA02012472A (es) Compuestos quimicos.
CO5021190A1 (es) Agentes terapeuticos